FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C. 20549
-------------	------------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Curran Terrie				2. Issuer Name and Ticker or Trading Symbol Phathom Pharmaceuticals, Inc. [PHAT]										all app	,	ng Per	rson(s) to Is 10% Over (s)	wner	
(Last) (First) (Middle) C/O PHATHOM PHARMACEUTICALS, INC. 100 CAMPUS DRIVE, SUITE 102						3. Date of Earliest Transaction (Month/Day/Year) 03/01/2023									belov		Chief	below)	, ,
(Street) FLORHA PARK	AM NJ	0		4. If Amendment, Date of Original Filed (Month/Day/Year)									i. Indivine)	vidual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(Sta		Zip)																
		Table	I - No	on-Deriva	tive S	Secui	rities /	Ac	quire	d, Dis	sposed of	f, or B	enefic	ially	Own	ed			
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Y				Year)	Execution Date,					Acquired (A) or (D) (Instr. 3, 4 a		nd 5) Securi Benefi		ities For icially (D) d Following (I) (n: Direct or Indirect ostr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount	(A) or (D)	Price		Transa	action(s) 3 and 4)			(111311. 4)
Common Stock 03/01/202					23			S ⁽¹⁾		1,436	D	\$8.54	11(2) 1		175,371		D		
Common Stock															2,235.9				by 401(k)
		Tal	ble II	- Derivati							osed of, convertib				Owne	d			
1. Title of 2. 3. Transaction Darivative Conversion Date Execution Date, Security or Exercise (Month/Day/Year) if any				4. Transa	4. Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisal Expiration Date (Month/Day/Year		7. Title and Amount of Securities Underlying Derivative Security (Insi 3 and 4)		8. P Der Sec	rice of ivative curity tr. 5)	tive derivative ty Securities		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership tt (Instr. 4)	
	of Respons				Code	(A)	(D)	Date Exerc	cisable	Expiration Date	Title	Amount or Number of Shares	r						

- $1. \ The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 26, 2022.$
- 2. Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$8.53 to \$8.7614. The reporting person undertakes to provide the Issuer, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

/s/ Larry Miller, Attorney-in-Fact for Terrie Curran

03/03/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.